Clinical trial · Observational
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Transformed Splenic Marginal Zone Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Prevalence of mutations, copy number abnormalities and structural variants at SMZL diagnosis and at HT
- timeFrame
- 30 months: from the end of samples collection to the end of study analysis
- measure
- Quantification and qualification of lesions acquired at the time of HT.
- timeFrame
- 30 months: from the end of samples collection to the end of study analysis
- measure
- Prevalence of clonal relationship between SMZL and HT
- timeFrame
- 30 months: from the end of samples collection to the end of study analysis
Secondary outcomes (4)
- measure
- Prevalence of HT molecular subtypes defined by genetic lesions
- timeFrame
- 30 months: from the end of samples collection to the end of study analysis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adults aged 18 years or older, regardless of the gender; 2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease); 3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available; 4. Availability of the baseline and follow-up annotations. Exclusion Criteria: * None
References
Publications (0)
Data not yet available